ATE277629T1 - Morphogenische behandlung des chronischen nierenversagens - Google Patents
Morphogenische behandlung des chronischen nierenversagensInfo
- Publication number
- ATE277629T1 ATE277629T1 AT97922726T AT97922726T ATE277629T1 AT E277629 T1 ATE277629 T1 AT E277629T1 AT 97922726 T AT97922726 T AT 97922726T AT 97922726 T AT97922726 T AT 97922726T AT E277629 T1 ATE277629 T1 AT E277629T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- chronic kidney
- kidney failure
- risk
- morphogenic
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 3
- 208000020832 chronic kidney disease Diseases 0.000 title abstract 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 title abstract 2
- 230000000921 morphogenic effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 abstract 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 abstract 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 abstract 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 abstract 1
- 229940112869 bone morphogenetic protein Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002188 osteogenic effect Effects 0.000 abstract 1
- 238000012959 renal replacement therapy Methods 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/643,321 US6498142B1 (en) | 1996-05-06 | 1996-05-06 | Morphogen treatment for chronic renal failure |
| PCT/US1997/007816 WO1997041881A1 (en) | 1996-05-06 | 1997-05-06 | Morphogen treatment for chronic renal failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE277629T1 true ATE277629T1 (de) | 2004-10-15 |
Family
ID=24580305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97922726T ATE277629T1 (de) | 1996-05-06 | 1997-05-06 | Morphogenische behandlung des chronischen nierenversagens |
| AT97923567T ATE245997T1 (de) | 1996-05-06 | 1997-05-06 | Therapien des chronischen nierenversagens |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97923567T ATE245997T1 (de) | 1996-05-06 | 1997-05-06 | Therapien des chronischen nierenversagens |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US6498142B1 (OSRAM) |
| EP (2) | EP0914146B1 (OSRAM) |
| JP (4) | JP2000510835A (OSRAM) |
| AT (2) | ATE277629T1 (OSRAM) |
| AU (2) | AU2832297A (OSRAM) |
| CA (2) | CA2254953C (OSRAM) |
| DE (2) | DE69730966T2 (OSRAM) |
| DK (2) | DK0914146T3 (OSRAM) |
| ES (2) | ES2230604T3 (OSRAM) |
| PT (2) | PT910400E (OSRAM) |
| WO (2) | WO1997041881A1 (OSRAM) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| CA2104678C (en) * | 1991-03-11 | 2002-05-14 | Charles M. Cohen | Protein-induced morphogenesis |
| US20030167492A1 (en) | 1994-07-08 | 2003-09-04 | Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same |
| US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| ES2226125T3 (es) * | 1997-05-05 | 2005-03-16 | Curis, Inc. | Terapias para insuficiencia renal aguda. |
| AU7473098A (en) * | 1997-05-07 | 1998-11-27 | Biogen, Inc. | Novel therapies for cystic kidney disease |
| EP0896825B1 (en) | 1997-08-14 | 2002-07-17 | Sulzer Innotec Ag | Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors |
| US6203788B1 (en) * | 1997-09-29 | 2001-03-20 | Adherex Inc. | Compounds and methods for regulating cell adhesion |
| AU1706499A (en) * | 1997-12-04 | 1999-06-16 | Curis, Inc. | Maintenance of smooth muscle integrity by morphogenic proteins |
| BR9912548A (pt) * | 1998-07-28 | 2002-01-29 | Univ Johns Hopkins Med | Fator-11 de diferenciação de crescimento |
| US6992066B2 (en) | 1998-10-16 | 2006-01-31 | Zimmer Orthobiologics, Inc. | Povidone-containing carriers for polypeptide growth factors |
| US7087577B2 (en) * | 1998-10-16 | 2006-08-08 | Zimmer Orthobiologies, Inc. | Method of promoting natural bypass |
| CA2384948C (en) * | 1999-09-14 | 2013-07-16 | Biogen, Inc. | Therapies for chronic renal failure using one or more integrin antagonists |
| US20020173453A1 (en) * | 2000-12-15 | 2002-11-21 | Rama Akella | Method of treating renal injury |
| US7763769B2 (en) | 2001-02-16 | 2010-07-27 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7700819B2 (en) | 2001-02-16 | 2010-04-20 | Kci Licensing, Inc. | Biocompatible wound dressing |
| US7232802B2 (en) * | 2001-12-21 | 2007-06-19 | Zimmer Orthobiologics, Inc. | Compositions and methods for promoting myocardial and peripheral angiogenesis |
| US7622562B2 (en) | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
| US20050272649A1 (en) * | 2002-08-28 | 2005-12-08 | Hruska Keith A | Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure |
| US7576052B2 (en) | 2003-10-17 | 2009-08-18 | Joslin Diabetes Center, Inc. | Methods and compositions for modulating adipocyte function |
| US7844367B2 (en) | 2003-12-23 | 2010-11-30 | Rain Bird Corporation | Code replacement for irrigation controllers |
| CA2557999C (en) * | 2004-03-30 | 2013-11-12 | Ilypsa, Inc. | Methods and compositions for treatment of ion imbalances |
| US7459527B2 (en) * | 2004-03-31 | 2008-12-02 | Xencor, Inc. | BMP-7 variants with improved properties |
| WO2006130690A2 (en) | 2005-06-01 | 2006-12-07 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| US7771995B2 (en) * | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| JP2009515529A (ja) | 2005-11-14 | 2009-04-16 | メリアル リミテッド | 腎不全のための遺伝子療法 |
| US20090004159A1 (en) * | 2006-01-24 | 2009-01-01 | The Board Of Trustees Of The University Of Illinoi | Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells |
| JP2009524436A (ja) | 2006-01-24 | 2009-07-02 | ノースフィールド ラボラトリーズ、インコーポレイテッド | 重合したヘモグロビンの培地、並びに島細胞の単離及び移植におけるその使用 |
| US20080090765A1 (en) * | 2006-05-25 | 2008-04-17 | The Trustees Of Columbia University In The City Of New York | Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage |
| PL2035835T3 (pl) | 2006-05-30 | 2012-05-31 | Antibodyshop As | Sposoby szybkiej oceny ciężkości urazu |
| US7722665B2 (en) | 2006-07-07 | 2010-05-25 | Graft Technologies, Inc. | System and method for providing a graft in a vascular environment |
| EP2047862B9 (en) | 2006-07-21 | 2013-04-10 | Chugai Seiyaku Kabushiki Kaisha | Remedy for renal disease |
| EP2114390A2 (en) * | 2006-12-15 | 2009-11-11 | Ruprecht-Karls-Universität Heidelberg | Methods for treating podocyte-related disorders |
| EP2148706A2 (en) * | 2007-04-24 | 2010-02-03 | Advanced Technologies and Regenerative Medicine, LLC | Engineered renal tissue |
| DE102007034580B4 (de) * | 2007-07-13 | 2012-11-08 | NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen | Biomaterial basierend auf einem hydrophilen polymeren Träger |
| US20090155245A1 (en) * | 2007-12-18 | 2009-06-18 | Fang Carrie H | Treatment for Organ Regeneration with Combination of Drug and Biologics |
| CN102083969A (zh) * | 2008-05-06 | 2011-06-01 | 乔斯林糖尿病中心股份有限公司 | 诱导褐色脂肪形成的方法和组合物 |
| WO2009157165A1 (ja) * | 2008-06-24 | 2009-12-30 | 株式会社根本杏林堂 | 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法 |
| KR20110073471A (ko) * | 2008-08-28 | 2011-06-29 | 아스튜트 메디컬 인코포레이티드 | 신손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물 |
| WO2010025434A1 (en) * | 2008-08-29 | 2010-03-04 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ619918A (en) * | 2008-10-21 | 2015-04-24 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US8778615B2 (en) | 2008-10-21 | 2014-07-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2010054389A1 (en) | 2008-11-10 | 2010-05-14 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN102272328B (zh) * | 2008-11-22 | 2014-06-18 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
| AU2010279249B2 (en) | 2009-02-06 | 2015-08-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2010210535B2 (en) * | 2009-02-06 | 2015-12-10 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| JP5819733B2 (ja) * | 2009-02-12 | 2015-11-24 | ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ | 障害および疾患に対する全身治療のためのＴＧＦ−βスーパーファミリーメンバー含有タンパク質の末梢投与 |
| JP5819734B2 (ja) | 2009-02-12 | 2015-11-24 | ストライカー コーポレイションＳｔｒｙｋｅｒ Ｃｏｒｐｏｒａｔｉｏｎ | ＴＧＦ−βスーパーファミリーメンバー含有タンパク質の最小に侵襲性の全身送達のための組成物および方法 |
| AU2010223268B2 (en) | 2009-03-12 | 2015-04-23 | Haase Investments Gmbh | Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity |
| US20110002897A1 (en) | 2009-06-11 | 2011-01-06 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
| WO2011035094A1 (en) | 2009-09-17 | 2011-03-24 | Stryker Corporation | Buffers for controlling the ph of bone morphogenetic proteins |
| NZ599773A (en) | 2009-11-07 | 2014-09-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| NZ702527A (en) | 2009-12-20 | 2016-07-29 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| CN102822197A (zh) | 2009-12-22 | 2012-12-12 | 史赛克公司 | 具有降低的免疫原性的bmp-7变体 |
| JP2013519095A (ja) | 2010-02-05 | 2013-05-23 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| JP5998057B2 (ja) | 2010-02-26 | 2016-11-30 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断と予後のための方法と組成物 |
| ES2667066T3 (es) | 2010-05-24 | 2018-05-09 | The Trustees Of Columbia University In The City Of New York | Proteínas NGAL mutantes y usos de las mismas |
| NZ605561A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| AU2011269775B2 (en) | 2010-06-23 | 2015-01-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| RU2013104029A (ru) | 2010-08-20 | 2014-09-27 | ВАЙЕТ ЭлЭлСи | Сконструированные остеогенные белки |
| US9688735B2 (en) | 2010-08-20 | 2017-06-27 | Wyeth Llc | Designer osteogenic proteins |
| EP3540440B1 (en) | 2011-12-08 | 2022-09-28 | Astute Medical, Inc. | Methods and uses for evaluating renal injury and renal status |
| CN119405686A (zh) | 2012-10-08 | 2025-02-11 | 维福(国际)有限公司 | 治疗高血压和高血钾症的钾结合剂 |
| EP2925337B1 (en) | 2012-11-21 | 2019-07-03 | The Trustees of Columbia University in the City of New York | Mutant ngal proteins and uses thereof |
| JP6681195B2 (ja) | 2013-01-17 | 2020-04-15 | アスチュート メディカル，インコーポレイテッド | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
| US8956829B2 (en) | 2013-01-25 | 2015-02-17 | Warsaw Orthopedic, Inc. | Human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US9051389B2 (en) | 2013-01-25 | 2015-06-09 | Warsaw Orthopedic, Inc. | Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5) |
| US9169308B2 (en) | 2013-01-25 | 2015-10-27 | Warsaw Orthopedic, Inc. | Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies |
| US9359417B2 (en) | 2013-01-25 | 2016-06-07 | Warsaw Orthopedic, Inc. | Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5) |
| US8945872B2 (en) | 2013-01-25 | 2015-02-03 | Warsaw Orthopedic, Inc. | Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein |
| EP2784083A1 (en) | 2013-03-28 | 2014-10-01 | Charité - Universitätsmedizin Berlin | Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity |
| CN105705951B (zh) * | 2013-11-11 | 2020-03-31 | 通用电气公司 | 用于减少转子速度测量中误差的方法 |
| EP2944326B1 (en) | 2014-05-16 | 2018-11-21 | Cyanagen Srl | Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases |
| JP7199809B2 (ja) | 2015-02-13 | 2023-01-06 | ファクター バイオサイエンス インコーポレイテッド | 核酸製品及びその投与方法 |
| EP3465201A4 (en) | 2016-06-06 | 2020-08-26 | Astute Medical, Inc. | MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR |
| EP3500585A4 (en) | 2016-08-17 | 2020-04-01 | Factor Bioscience Inc. | NUCLEIC ACID PRODUCTS AND METHODS OF ADMINISTRATION |
| JP2019039673A (ja) * | 2017-08-22 | 2019-03-14 | セイコーエプソン株式会社 | 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1156741B (it) * | 1978-05-15 | 1987-02-04 | Sigma Tau Ind Farmaceuti | Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi |
| US4342828A (en) | 1979-07-20 | 1982-08-03 | Morinaga Milk Industry Co., Ltd. | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
| US4627839A (en) * | 1985-11-21 | 1986-12-09 | American Hospital Supply Corporation | Patient controlled analgesia conversion |
| US5013649A (en) | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
| IL83003A (en) | 1986-07-01 | 1995-07-31 | Genetics Inst | Osteoinductive factors |
| US5011691A (en) | 1988-08-15 | 1991-04-30 | Stryker Corporation | Osteogenic devices |
| US5266683A (en) | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
| US5045452A (en) | 1988-09-02 | 1991-09-03 | Brigham And Women's Hospital | Method for evaluating nephrotoxicity |
| DK0429570T3 (da) | 1989-03-28 | 1998-04-27 | Genetics Inst | Osteoinducerende præparater |
| WO1991018098A1 (en) | 1990-05-16 | 1991-11-28 | Genetics Institute, Inc. | Bone and cartilage inductive proteins |
| JPH0426624A (ja) * | 1990-05-18 | 1992-01-29 | Tsumura & Co | 慢性腎不全改善剤 |
| EP0533840B1 (en) * | 1990-06-22 | 1996-12-11 | E.I. Du Pont De Nemours And Company | Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists |
| US5849686A (en) * | 1991-03-11 | 1998-12-15 | Creative Biomolecules, Inc. | Morphogen-induced liver regeneration |
| CA2104678C (en) * | 1991-03-11 | 2002-05-14 | Charles M. Cohen | Protein-induced morphogenesis |
| US7056882B2 (en) * | 1991-03-11 | 2006-06-06 | Curis, Inc. | Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| US6077823A (en) * | 1991-03-11 | 2000-06-20 | Creative Biomolecules, Inc. | Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury |
| US6194376B1 (en) * | 1991-03-11 | 2001-02-27 | Creative Biomolecules, Inc. | Method for modulating inflammatory response comprising administering morphogen |
| JP3627985B2 (ja) | 1991-03-11 | 2005-03-09 | キュリス インコーポレイテッド | タンパク質により誘導される形態形成 |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| JP3693338B2 (ja) | 1991-08-30 | 2005-09-07 | キュリス インコーポレイテッド | 組織形成因子誘導による炎症反応の調節 |
| ATE308336T1 (de) | 1991-08-30 | 2005-11-15 | Curis Inc | Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten |
| EP1033574A3 (en) | 1991-08-30 | 2004-01-28 | Curis, Inc. | Morphogenic protein screening method |
| US6120760A (en) * | 1992-02-12 | 2000-09-19 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung | Growth/differentiation factors of the TGF-β family |
| JP3981405B2 (ja) | 1992-07-31 | 2007-09-26 | ストライカー・コーポレーション | 形態形成蛋白質溶解型複合体，及びその組成 |
| CA2141556A1 (en) | 1992-07-31 | 1994-02-17 | Thangavel Kuberasampath | Morphogen-enriched dietary composition |
| PT653942E (pt) | 1992-07-31 | 2003-11-28 | Curis Inc | Regeneracao e reparacao de nervos induzidos por morfogenios |
| ATE162078T1 (de) | 1992-09-16 | 1998-01-15 | Creative Biomolecules Inc | Morphogeninduzierte regenerierung der leber |
| JPH08503198A (ja) | 1992-11-03 | 1996-04-09 | クリエイティブ バイオモレキュルズ，インコーポレイテッド | Ｏｐ−３誘導形態形成 |
| US5372335A (en) | 1992-12-18 | 1994-12-13 | Scott H. Yenzer | Aerial marker ball and method of placement |
| EP0687272B1 (en) | 1993-03-04 | 2007-01-17 | Stryker Corporation | Method and compositions for recombinant osteogenic protein production |
| US5631159A (en) | 1993-09-22 | 1997-05-20 | Creative Biomolecules, Inc. | Lipid-modified serum free media |
| US5585237A (en) | 1993-10-25 | 1996-12-17 | Creative Biomolecules, Inc. | Methods and compositions for high protein production from recombinant DNA |
| CA2176709A1 (en) * | 1993-11-15 | 1995-05-26 | Howard R. Higley | Method of treating renal disease by administering igf-i and igfbp-3 |
| US5525621A (en) * | 1994-05-20 | 1996-06-11 | Cytos Pharmaceuticals Llc | Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses |
| US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| US5723411A (en) * | 1995-10-31 | 1998-03-03 | E. I. Du Pont De Nemours And Company | Herbicidal pyridazinones |
| WO1997034618A1 (en) * | 1996-03-22 | 1997-09-25 | The General Hospital Corporation | Administration of polypeptide growth factors following central nervous system ischemia or trauma |
| US5820589A (en) * | 1996-04-30 | 1998-10-13 | Medtronic, Inc. | Implantable non-invasive rate-adjustable pump |
| US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
| US5879908A (en) * | 1997-04-30 | 1999-03-09 | Smithkline Beecham Corporation | CRFG-1a, a target and marker for chronic renal failure |
| US7147839B2 (en) * | 1998-05-29 | 2006-12-12 | Curis, Inc. | Methods for evaluating tissue morphogenesis and activity |
-
1996
- 1996-05-06 US US08/643,321 patent/US6498142B1/en not_active Expired - Lifetime
-
1997
- 1997-05-06 DK DK97922726T patent/DK0914146T3/da active
- 1997-05-06 PT PT97923567T patent/PT910400E/pt unknown
- 1997-05-06 AU AU28322/97A patent/AU2832297A/en not_active Abandoned
- 1997-05-06 AT AT97922726T patent/ATE277629T1/de active
- 1997-05-06 DK DK97923567T patent/DK0910400T3/da active
- 1997-05-06 WO PCT/US1997/007816 patent/WO1997041881A1/en not_active Ceased
- 1997-05-06 AT AT97923567T patent/ATE245997T1/de not_active IP Right Cessation
- 1997-05-06 DE DE69730966T patent/DE69730966T2/de not_active Expired - Lifetime
- 1997-05-06 ES ES97922726T patent/ES2230604T3/es not_active Expired - Lifetime
- 1997-05-06 CA CA002254953A patent/CA2254953C/en not_active Expired - Fee Related
- 1997-05-06 US US08/851,628 patent/US6861404B1/en not_active Expired - Fee Related
- 1997-05-06 CA CA002254954A patent/CA2254954C/en not_active Expired - Fee Related
- 1997-05-06 AU AU29339/97A patent/AU2933997A/en not_active Abandoned
- 1997-05-06 ES ES97923567T patent/ES2203803T3/es not_active Expired - Lifetime
- 1997-05-06 EP EP97922726A patent/EP0914146B1/en not_active Expired - Lifetime
- 1997-05-06 DE DE69723845T patent/DE69723845T2/de not_active Expired - Lifetime
- 1997-05-06 JP JP09540150A patent/JP2000510835A/ja active Pending
- 1997-05-06 JP JP54021197A patent/JP4766722B2/ja not_active Expired - Fee Related
- 1997-05-06 PT PT97922726T patent/PT914146E/pt unknown
- 1997-05-06 WO PCT/US1997/007655 patent/WO1997041880A1/en not_active Ceased
- 1997-05-06 EP EP97923567A patent/EP0910400B1/en not_active Expired - Lifetime
-
2004
- 2004-12-17 US US11/016,499 patent/US7524817B2/en not_active Expired - Fee Related
-
2009
- 2009-03-16 US US12/404,559 patent/US8017580B2/en not_active Expired - Fee Related
- 2009-05-26 JP JP2009126963A patent/JP5247593B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-11 US US13/207,584 patent/US8377878B2/en not_active Expired - Fee Related
-
2012
- 2012-08-14 JP JP2012179876A patent/JP2012229268A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE277629T1 (de) | Morphogenische behandlung des chronischen nierenversagens | |
| FI960809L (fi) | Hermoregeneraatio käyttäen ihmisen luun morfogeneettisiä proteiineja | |
| ATE278414T1 (de) | Therapien zur behandlung von akutem nierenversagen | |
| NO982436D0 (no) | Apparat for oppvarming av blod | |
| HUP9700603A1 (hu) | Gyógyászati készítmény véralvadási zavarok kezelésére | |
| DE60020613D1 (de) | (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen | |
| TR199802421T2 (xx) | Doku yenilenmesini d�zenleyen maddeler. | |
| EP0570916A3 (en) | Serum albumin, recombinant human, preparation process and pharmaceutical composition. | |
| NO970536D0 (no) | Behandlingssystem for avgitt blod med skrå reguleringsgrenseflate | |
| DE69432582D1 (de) | System zur Administration von Flüssigkeiten bei mehreren Patienten | |
| IS2925B (is) | Ákvörðun á batahorfum sjúklings sem undirgengst meðhöndlun við Alzheimer-sjúkdómi | |
| MXPA03011386A (es) | Proteina de union para su uso en la regeneracion de hueso o cartilago. | |
| NO972391L (no) | 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav | |
| EP0871457A4 (en) | ISOLATED CURRENT CELLS AND METHODS FOR THE USE THEREOF | |
| DE69714451D1 (de) | Prionbindende proteine und deren verwendungen | |
| MX9101958A (es) | Inhibidores de acat de urea de aminosulfonilo | |
| EP1169058A4 (en) | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4 Protease | |
| DE69916488D1 (de) | Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren | |
| ATE302021T1 (de) | Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52 | |
| ATE238796T1 (de) | Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten | |
| ATE265225T1 (de) | Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen | |
| ATE306275T1 (de) | Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten | |
| DK0495226T3 (da) | Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma | |
| DE69523250D1 (de) | Verwendung von Osteoblast-Proliferationsfaktor | |
| DK0834316T3 (da) | Anvendelse af sulbutiamin til behandling af psykomotoriske eller psykointellektuelle problemer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0914146 Country of ref document: EP |
|
| EEIH | Change in the person of patent owner |